Patient Information
- 1. NETs
- (Category)
- Created on 30 November -0001
- 2. IAEA Guidance on PRRNT for NETs
- (In the News)
- A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of ...
- Created on 29 September 2013
- 3. Zentralklinik Bad Berka Named ENETS Center of Excellence
- (In the News)
- January 2011 - European Neuroendocrine Tumor Society has certified Zentralklink Bad Berka as an ENETS Centers of Excellence. The certification states that center meets all quality standards defined ...
- Created on 06 April 2011
- 4. Lutathera Approved in the US
- (News)
- ... (FDA) has approved the new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), ...
- Created on 27 June 2018
- 5. Videos from SNMMI Annual Meeting
- (News)
- Videos from Patient Education Day on NETs from the SNMMI Annual Meeting Philidelphia, June 2018 Introduction to Theranostic from Zentralklink Bad Berka Bb8Ts5HWS40
- Created on 27 June 2018
- 6. Lutathera Approved in the European Union
- (News)
- ... and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.” This approval allows for the marketing of lutetium (177Lu) oxodotreotide* (Lutathera®) in all ...
- Created on 02 October 2017
- 7. 2014 SNMMI Patient Education Day
- (News)
- For the second year in a row, NorCal CarciNET Community and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a patient education day during the SNMMI's Annual Meeting. The program took ...
- Created on 18 August 2014
- 8. Updates from the Ga68 Working Group
- (News)
- Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the ...
- Created on 18 August 2014
- 9. Ga68 - Orphan Drug Announcement
- (In the News)
- BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine ...
- Created on 20 November 2013
- 10. SNM 2012 Image of the Year: Bi-213-DOTATOC for a New Treatment for GEP-NET Tumors Resistant to Standard Therapies:
- (In the News)
- ... tumors (GEP-NETs) that do not respond to beta therapy. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNM's 2012 Annual Meeting in Miami Beach, ...
- Created on 20 June 2012
- 11. One More Thing.. - Steve Jobs Passing
- (In the News)
- Steve Jobs lost his battle with NETs in October 2011, many sites have chronicled his medical care and the various medical treatments he pursued including PRRT. For a detailed look at his medical history ...
- Created on 24 October 2011
- 12. First World Congress of Ga-68 and PRRNT - an Overwhelming Success
- (Conferences)
- ... of Neuroendocrine Tumors (NETs) using Peptide Receptor RadioNuclide Thearpy (PRRNT). The event was orginized by Prof. Dr. Richard P. Baum of Zentralklink, Bad Berka and Prof. Dr. Frank Rösch of the Institute ...
- Created on 08 September 2011
- 13. Steve Jobs resigns from Apple
- (In the News)
- Aug 24, 2011 - Steve Jobs - Apple's CEO resigned today saying he "could no longer meet my duties and expectations as Apple's CEO'. Mr. Jobs has been battling pancreatic neuroendocrine cancer since 2004 ...
- Created on 25 August 2011
- 14. CCAN NET Cancer Patients Conference Long Island
- (Past Conferences )
- CCAN's annual conference was held in Long Island, New York on August 20th 2011. The theme of the day long conference was "Multidisciplinary Approach to the Diagnosis Treatment and Monitoring of NETs." Speakers ...
- Created on 20 August 2011
- 15. FAQs
- (FAQs)
- ... NETs patient should also evaluate their best treatment option before any treatment. Does PRRT cause kidney damage? PRRT could damage kidneys, but the risk is relatively low. Considerable research has ...
- Created on 13 April 2011
- 16. Elizabeth W.
- (Bad Berka)
- ... choice for someone like me who had tried and failed at most of the known treatments for NETs. The only obstacle was to get insurance coverage and see if Dr. Baum would accept me as a patient. Next, ...
- Created on 22 March 2011
- 17. How to contact the Clinic
- (Background)
- ... is: THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging ENETS Center of Excellence Zentralklinik Bad Berka 99437 Bad Berka, Germany Tel. +49 364 585 2200 Fax +49 364 585 3515 ...
- Created on 15 February 2011
- 18. Centers that offer PRRT
- (PRRT)
- ... Montenegro, Bosnia and Herzegovina and Kosova region will accept patinets from outside the region. Erasmus MC University Medical Center in Rotterdam (LU177 only) University of Basel Uppsala University ...
- Created on 20 January 2011
- 19. Information for Referring Physicians
- (General MD)
- This section is for doctors who are considering the selection of PRRT to treat one of their patients. Considering PRRT for a Patient: What a physician should look for Progressive, somatostatin receptor ...
- Created on 19 July 2010
- 20. What is PRRT?
- (PRRT)
- ... tumors include gastroenteropancreatic tumors (socalled GEP-NETs), e.g. arising from the small bowel (often called carcinoid tumors), the pancreas, duodenum or stomach, but also from the large bowel or ...
- Created on 19 July 2010